Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T
A phase Ib/II study demonstrated that mosunetuzumab (Lunsumio) plus polatuzumab vedotin (Polivy) induced durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL), including patients who relapsed after CAR T-cell therapy. The findings were presented at the recent American Society of Hematology (ASH) annual meeting and simultaneously published in Nature Medicine. In this […]
Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPC
A reduced-dose schedule of cabazitaxel (Jevtana) plus prophylactic granulocyte colony-stimulating factor (G-CSF) should be offered to older men with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III randomized CABASTY trial. Rates of grade 3 or higher neutropenia or neutropenic complications were about 12 times lower with biweekly cabazitaxel 16 mg/m2 plus […]
FDA OKs New Frontline Endometrial Cancer Regimen, First in Decades
The FDA approved the immune checkpoint inhibitor dostarlimab (Jemperli) plus chemotherapy as a frontline option for certain patients with advanced or recurrent endometrial cancer, the agency announced on Monday. For adults with primary advanced or recurrent endometrial cancer that is mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H), dostarlimab is now approved as part of a […]
Trial Suggests Optimal Approach to Unresectable CRC Liver Mets
For patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI plus bevacizumab (Avastin) was the “preferred” systemic induction regimen for those with a right-sided or RAS- or BRAF V600E-mutated primary tumor, according to a phase III randomized trial. Among these patients, the median progression-free survival (PFS) was 9.0 months in those receiving FOLFOX or FOLFIRI […]
FDA Staff Not Sold on Broad Olaparib Indication in Metastatic CRPC
Olaparib (Lynparza) plus abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) is only clearly effective in patients with BRCA mutations, FDA staff contended in a briefing document released ahead of an advisory committee meeting. On Friday, the FDA is asking its Oncologic Drugs Advisory Committee (ODAC) to weigh in on whether a […]
Combo Falters in Papillary Renal Cancer, but Some Promise in MET-Driven Subset
Treatment with an investigational MET inhibitor plus a PD-L1 inhibitor induced responses in fewer than a third of patients with metastatic papillary renal cancer, but the combination showed promise for one subgroup, findings from the phase II CALYPSO trial showed. In the single-arm study, 12 of 41 patients (29%, 95% CI 16-46) had a confirmed […]
ICI/TKI Combo Maintains Survival Benefit in Advanced RCC
SAN FRANCISCO — First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful survival benefits in advanced renal cell carcinoma (RCC). An update of the CheckMate 9ER trial, which compared the immune checkpoint inhibitor/tyrosine kinase inhibitor (TKI) doublet with the TKI sunitinib (Sutent), showed that after 44 months of median follow-up, median progression-free survival […]
Escalated ADT Falls Short in Men With High-Risk Features After Prostatectomy
SAN FRANCISCO — Add-on hormone therapy plus an antiandrogen to salvage radiation and androgen deprivation therapy (ADT) did not boost survival outcomes in high-risk prostate cancer. In the FORMULA-509 trial, the addition of 6 months of abiraterone acetate (Zytiga) and apalutamide (Erleada) to salvage radiation (RT) and 6 months of ADT with a GnRH agonist […]
Adding Talazoparib to Enzalutamide Boosts PFS in Metastatic Prostate Cancer
SAN FRANCISCO — Treatment with the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) compared with enzalutamide plus placebo in patients with metastatic castration-resistant prostate cancer (mCRPC), the phase III TALAPRO-2 trial showed. Among 805 randomized patients, rPFS assessed by blinded independent central review was not reached in those who […]
Keytruda Plus T-VEC Falls Short in Unresectable Melanoma
Pembrolizumab (Keytruda) plus intratumoral talimogene laherparepvec (T-VEC, Imlygic) did not significantly improve survival in unresectable melanoma as compared with pembrolizumab alone, an international phase III trial showed. Although the combination improved median progression-free survival (PFS) by almost 6 months (14.3 vs 8.5 months), the difference did not achieve statistical significance (P=0.13). Median overall survival (OS) […]